
-
About Us
-
History
Notice: Undefined offset: 3 in /home/host/nexelshop/www/html/_skin/mdp/layout/inc_navigation_middle.php on line 86
History
Introducing NEXEL’s History
2020s
-
- May
- MoU signed with Chonnam National University Hospital
- Apr
- Strategic partnership with Nanion Technologies to open reference lab in Korea for CardioExcyte96 FLEXcyte96
2019s
-
- Aug
- Completed Series B funding
- May
- Novartis drug development team(VP level) visits NEXEL HQ
- Mar
- Distribution agreement signed with Cambridge Bioscience in the U.K. and Ireland for hiPSC-derived cell products
2018s
-
- Jun
- Innobiz Certification
- May
- Commercial license (non-exclusive) for hiPSC-derived cell products obtained from iPS Academia Japan
- Mar
- ISO9001 certification
2017s
-
- Dec
- Completed Series A funding
- Sep
- Invited to Novo Nordisk global collaboration business (with KOTRA)
- Aug
- MoU signed with T&R Biofab for the development of bioprinting technology using stem-cell derived cells
- May
- Distribution agreement with BOYA Medical for the distribution of iPSC-derived cell products
- Jan
- Domestic launch of cell products
2016s
-
- Dec
- Tech. transfer of 6 patents from Korea University Industry-Academic Cooperation Foundation
- Nov
- License-in of cardiomyocyte differentiation technology from KIT
- Sep
- MoU signed for the development of toxicology platfoms using stem-cell derived cells with Korea Institute of Toxicology (KIT)
- Mar
- Corporate affiliated research institute certified
- Feb
- Venture company certified
2015s
-
- May
- Name changed to NEXEL Co., Ltd.
2014s
-
- Nov
- Picked as family company to Korea University Life Sciences College
- Sep
- MoU signed with IMPLAD China
2013s
-
- Mar
- MoU signed with Korea University
2012s
-
- Sep
- Founding of NEXCELL Bio